U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H14Cl2N2O2
Molecular Weight 349.211
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOXAZOLAM

SMILES

ClC1=CC=C2NC(=O)CN3CCOC3(C4=CC=CC=C4Cl)C2=C1

InChI

InChIKey=ZIXNZOBDFKSQTC-UHFFFAOYSA-N
InChI=1S/C17H14Cl2N2O2/c18-11-5-6-15-13(9-11)17(12-3-1-2-4-14(12)19)21(7-8-23-17)10-16(22)20-15/h1-6,9H,7-8,10H2,(H,20,22)

HIDE SMILES / InChI
Molecular Formula C17H14Cl2N2O2
Molecular Weight 349.211
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Cloxazolam is an agonist of GABA-A receptor that was developed in Japan for the treatment of anxiety-disorders. The drug was marketed in Europe under the names Sepazon, Olcadil, Akton and Lubalix.

CNS Activity

Originator

Sankyo
35
Sources: www.ncbi.nlm.nih.gov/pubmed/4753311

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
OLCADIL

Approved Use

Emotional disorders such as anxiety, tension, restlessness; sleep disorders such as difficulty falling asleep, insomnia and early awakening; pre-medication prior to surgery.

Launch Date

2013
Primary
Approved
8583
OLCADIL

Approved Use

Emotional disorders such as anxiety, tension, restlessness; sleep disorders such as difficulty falling asleep, insomnia and early awakening; pre-medication prior to surgery.

Launch Date

2013
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2002.4 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1920.1 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
138.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
136.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/19488979/
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELORAZEPAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.26 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.26 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.26 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Disc. AE: Drowsiness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
0.3 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Disc. AE: Hyperactivity...
Other AEs: Drowsiness, Irritability...
AEs leading to
discontinuation/dose reduction:
Hyperactivity (1 pt)
Other AEs:
Drowsiness (5 patients)
Irritability (2 patients)
Appetite lost (1 pt)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
AEs

AEs

AESignificanceDosePopulation
Drowsiness 2 patients
Disc. AE
0.26 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.26 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.26 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Appetite lost 1 pt
0.3 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Hyperactivity 1 pt
Disc. AE
0.3 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Irritability 2 patients
0.3 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
Drowsiness 5 patients
0.3 mg/kg 1 times / day multiple, oral
Studied dose
Dose: 0.3 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.3 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21093730/
PubMed

PubMed

TitleDatePubMed
Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone.
2003-02-01
Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines.
2002-04
[A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent].
2000-04
Patents

Patents

04014916
10
20020035217
34

Sample Use Guides

In Vivo Use Guide
Symptoms of mild to moderate severity: a tablet (2 mg) and a half to three tablets per day, divided into two administrations; Symptoms of moderately severe to severe: 3 to 4 tablets per day divided in two administrations.The optimal therapeutic dosage should be determined individually by progressive adjustment. max recommended dose: 6 tablets (12 mg)/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:44 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:44 GMT 2025
Record UNII
GYL649Z0HY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOXAZOLAM
INN   MART.   MI   WHO-DD  
INN  
Official Name English
SEPAZON
Preferred Name English
cloxazolam [INN]
Common Name English
CLOXAZOLAM [JAN]
Common Name English
CLOXAZOLAM [MART.]
Common Name English
CLOXAZOLAM [MI]
Common Name English
10-CHLORO-11B-(O-CHLOROPHENYL)-2,3,7,11B-TETRAHYDRO-OXAZOLO(3,2-D) (1,4)BENZODIAZEPIN-6(5H)-ONE
Common Name English
Cloxazolam [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 2753
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
WHO-ATC N05BA22
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
NCI_THESAURUS C28197
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
WHO-VATC QN05BA22
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL2107254
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
MERCK INDEX
m3674
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY Merck Index
PUBCHEM
2816
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
NCI_THESAURUS
C79883
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
EVMPD
SUB06781MIG
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
SMS_ID
100000084056
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
WIKIPEDIA
CLOXAZOLAM
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
CAS
24166-13-0
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
DRUG CENTRAL
721
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
RXCUI
21311
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB01553
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
MESH
C005522
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
FDA UNII
GYL649Z0HY
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID0022854
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
INN
3400
Created by admin on Mon Mar 31 18:16:44 GMT 2025 , Edited by admin on Mon Mar 31 18:16:44 GMT 2025
PRIMARY
Related Record Type Details
Structure of CLOXAZOLAM, (S)-
ENANTIOMER -> RACEMATE
Structure of CLOXAZOLAM, (R)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of CLOXAZOLAM
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966